| Hint | Answer | % Correct |
|---|---|---|
| what is Parkinson's disease characterised by? | insidious onset, with slowing of voluntary movement, muscular rigidity, postural abnormality & tremors | 100%
|
| what are the 3 distinguishing features of Alzheimer's disease? | accumulation of senile plaques (b-amyloid accumulations) | 86%
|
| formation of numerous neurofibrillary tangles | 86%
| |
| what are examples of each? | levodopa | 86%
|
| what are the drugs used to treat Alzheimer's disease? | acetylcholinesterase inhibitors | 71%
|
| allosterically binding to GABAA receptors on post- synaptic neurons | 71%
| |
| amantadine | 71%
| |
| what is an example of a motor neuron disease? | amyotrophic lateral sclerosis (ALS) etc | 71%
|
| carbidopa | 71%
| |
| what is an example of each? | donepezil, rivastigmine, etc | 71%
|
| what drugs do we use to treat Parkinson's? | dopamine precursors | 71%
|
| dopamine receptor agonists | 71%
| |
| loss of cortical neurons (especially cholinergic neurons) | 71%
| |
| what are the physical effects of motor neuron disease? | loss of motor neurons and muscle control until the patient can no longer eat, speak, move or breathe, with respiratory failure being the usual cause of death | 71%
|
| memantine | 71%
| |
| what is the mechanism of action of each? | metabolic precursor of dopamine, that is converted to dopamine by aromatic L-amino acid decarboxylase (AADC) | 71%
|
| benzatropine | 57%
| |
| what are the mechanisms of action of the first drug thought to be? | binding to glutamate receptors to reduce the release of glutamate | 57%
|
| inhibitors of dopamine metabolism | 57%
| |
| NMDA receptor antagonists | 57%
| |
| preferentially blocking TTX-sensitive sodium channels, which are linked to neuronal damage | 57%
| |
| what are the drugs indicated specifically for motor neuron disease? | riluzole, baclofen, edaravone, tizanidine | 57%
|
| what is Parkinson's disease caused by? | the striatal deficiency of dopamine following neuronal degeneration within the substantia nigra | 57%
|
| uncompetitive antagonists at glutamatergic NMDA receptors | 57%
| |
| what is motor neuron disease? | a group of related neurodegenerative diseases that affect motor neurons and therefore voluntary muscle control | 43%
|
| antimuscarinic drugs | 43%
| |
| bromocriptine, pramipexole, etc | 43%
| |
| what is the mechanism of action of each? | preferentially inhibits acetylcholinesterase (AchE) in the CNS over peripheral enzymes | 43%
|
| what does pharmacological treatment aim to do for Parkinson's? | restore dopamine levels in basal ganglia | 43%
|
| inhibits AADC in peripheral tissues to increase availability of levodopa in the CNS by allowing more to cross the BBB before being converted to dopamine | 29%
| |
| selectively blocks activity at the M1 muscarinic acetylcholine receptor, reducing cholinergic activity in the basal ganglia and restoring the ‘balance’ of acetylcholine and dopamine | 29%
| |
| unknown, but thought to weakly inhibit the NMDA and nicotine receptors, as well as activate dopamine receptors | 14%
| |
| agonists at dopamine D2 receptors, working to restore dopamine signalling in the striatum | 0%
| |
| reduce the excitatory effect of acetylcholine | 0%
|